Dan Victor has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Amazon, Bristol Myers Squibb, Microsoft, and Palantir Technologies. The Motley Fool ...

Amsellem covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Supernus Pharmaceuticals, and Collegium Pharmaceutical. ;'> Currently, the analyst consensus on ...

Neuroscience technology company Brooklyn Health is using artificial intelligence to target a fundamental problem in neurology ...

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

Results from a new study help resolve the decade-long mystery of why many patients with the deadliest form of skin cancer do ...

Brian Peters started his new role as SVP of the AI Squared division at Apimeds Pharmaceuticals. Pharma market research firm Konovo named Tim Albury as CFO. Tenpoint Therapeutics announced the ...

The Seattle-based company came to ASCO25 with new data on its neuroendocrine tumor–treating lead therapy, with big vibes and ...

Lisocabtagene maraleucel significantly improved responses rates and survival outcomes among patients with relapsed or refractory chronic lymphocytic leukemia, according to findings presented at ASCO ...

Adjuvant nivolumab plus chemoradiotherapy “could be proposed as a new standard treatment,” said Jean Bourhis, MD, PhD.

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat ...